Why did you decide to participate in the Biomapas Academy?
The first time I heard about Biomapas Academy was from a friend who was already working in the pharmacy field. She sent me an advertisement for Biomapas Academy, which highly intrigued me. As I was in my last year of life science master studies, I wanted to discover my potential career possibilities and learn more about clinical trials. Therefore, without long thinking, I filled in the application form. I was very happy to be selected from quite many applicants and be invited to attend Biomapas Academy.
How was your experience during the three months?
We had four months of weekly lectures on different topics. They were related to the organization of clinical trials, regulatory affairs and pharmacovigilance of various medical products. Biomapas experts who resented the lectures even shared their personal experience and actual practical examples with us. We have been able to get acquainted with Biomapas company and its work specifics. Here we could expand our knowledge of the pharmaceutical industry.
How do you feel after graduating from the Academy?
I feel thrilled for taking a chance to participate in this unique project. After graduating from all the courses and tasks, I was absolutely honoured to be selected as the best student of Biomapas Academy 2020 and receive a scholarship. However, I mostly appreciate the valuable knowledge and experience I believe will be helpful for my future career. I think Biomapas Academy definitely contributes to the education of young professionals and is very useful, especially for those who want to get to know their professional opportunities better.
Biomapas Academy
What is Clinical Research? Regulatory Affairs? Pharmacovigilance?
Celebrating 25 Years of Biomapas
This year we marked 25 years since Biomapas was founded. What began as a local Lithuanian CRO has evolved into a global organization, delivering integrated regulatory affairs, pharmacovigilance, medical information, and clinical operations to clients across Europe,...
How Medical Information Insights Add Strategic Value to Pharma and Biotech
Why medical information is more than a compliance function — and how consistent, unified insight turns everyday inquiries into strategic value across safety, strategy, and decision-making.
Case Study: Transforming Medical Information Across 17 European Markets
How Biomapas helped a leading pharmaceutical company transform its Medical Information operations across Europe.
When Do Biotech Companies and Startups Need Pharmacovigilance
Many biotech startups assume pharmacovigilance begins after approval, but regulatory expectations and clinical trial complexity often require safety oversight much earlier. Learn when pharmacovigilance becomes essential and how to stay compliant as you scale.
How to Build Clinical Safety for Biotechs Without a Full Department
Discover how biotech companies can build scalable clinical safety management early, ensuring compliance, oversight, and efficient operations across development phases.
Biomapas Insights: Navigating Italian Regulatory Requirements and AIFA Updates
Clear guidance on Italian regulatory requirements for promotional materials and recent AIFA updates affecting pharmaceutical companies.
Clinical Safety Management in Pharma: How to Manage Risk Across the Drug Development Lifecycle
Learn how effective clinical trial safety management supports risk mitigation, regulatory compliance, and patient safety across all stages of drug development.
Global Case Processing in Pharmacovigilance: Practical Guide to Compliance, Quality, and Scale
As pharmacovigilance expands across markets, maintaining control becomes challenging. In this article, we explore key risks, regulatory differences, and scalable models for global case processing.
Case Study: International & Local Pharmacovigilance/Medical Information Services – Urgent Action
Discover how Biomapas delivered a seamless global and local transition for a pharmaceutical company, facing a critical Pharmacovigilance and Medical Information vendor transition with a non‑negotiable one‑month timeline.
Marketing Pharmaceutical Products in CIS/Eurasian Economic Union
Explore how pharmaceutical companies can successfully market products in CIS and EAEU countries, highlighting regulatory differences from the EU, recent legislative changes, and practical RA and pharmacovigilance considerations.
